Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia

Oncogene

Volumn 31, Issue 30, 2012, Pages 3536-3546

  Tailler, M ^a,b,c   Senovilla, L ^a,b,c   Lainey, E ^a,b,c   Thepot S ^a,c,d   Metivier D ^a,b,c   Sebert M ^a,c,d   Baud, V ^e,f,g   Billot, K ^e,f,g   Fenaux, P ^a,c,d   Galluzzi, L ^a,b,c   Boehrer, S ^a,c,d   Kroemer, G ^a,b,g,h,i   Kepp, O ^a,b,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d AVICENNE HOSPITAL   (France)

^e INSTITUT COCHIN   (France)

^f CNRS   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h CENTRE DE RECHERCHE DES CORDELIERS   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

apoptosis; HCS; HL 60; myeloblasts; necrosis

Indexed keywords

CASPASE; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OUABAIN; PYRITHIONE ZINC;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO CULTURE; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CHROMATIN; GRANULOCYTE PRECURSOR CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; MITOCHONDRIAL MEMBRANES; ORGANOMETALLIC COMPOUNDS; OUABAIN; PYRIDINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

STROPHANTHUS GRATUS;

EID: 84864375342     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.521     Document Type: Article

References (34)

1. BielawsKi K, Winnicka K, Bielawska A. (2006). Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull 29: 1493-1497.
2. Boehrer S, Ades L, Braun T, Galluzzi L, Grosjean J, Fabre C et al. (2008). Erlotinib exhibits antineoplastic offtarget effects in AML and MDS: a preclinical study. Blood 111: 2170-2180. (Pubitemid 351451531)
3. Burnett A, Wetzler M, Lowenberg B. (2011). Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29: 487-494.
4. Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G. (2002). Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 265: 39-47. (Pubitemid 34628803)
5. Chan G, Pilichowska M. (2007). Complete remission in a patient with acute myelogenous leukemia TREated with erlotinib for non small-cell lung cancer. Blood 110: 1079-1080. (Pubitemid 47267456)
6. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T et al. (2007). A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 67: 6253-6262. (Pubitemid 47037507)
7. Edwards BS, Young SM, Ivnitsky-Steele I, Ye RD, Prossnitz ER, Sklar LA. (2009). High-content screening: flow cytometry analysis. Methods Mol Biol 486: 151-165.
8. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH et al. (2009). Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 16: 1093-1107.
9. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G. (2007). Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 12: 803-813. (Pubitemid 46653289)
10. Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC et al. (2009). Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16: 281-294.
11. Hallbook H, Felth J, Eriksson A, Fryknas M, Bohlin L, Larsson R et al. (2011). Ex vivo activity of cardiac glycosides in acute leukaemia. PLoS One 6: e15718.
12. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L et al. (2008). Improved cellular pharmacoKinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68: 5301-5308.
13. Juncker T, CeRella C, Teiten MH, Morceau F, Schumacher M, Ghelfi J et al. (2011). UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem Pharmacol 81: 13-23.
14. Kepp O, Galluzzi L, LipinsKi M, Yuan J, Kroemer G. (2011). Cell death assays for drug discovery. Nat Rev Drug Discov 10: 221-237.
15. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS et al. (2008). Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175. (Pubitemid 351231180)
16. Kometiani P, Liu L, Askari A. (2005). Digitalis-induced signaling by Na +K+-ATPase in human breast cancer cells. Mol Pharmacol 67: 929-936. (Pubitemid 40365340)
17. Lamore SD, Cabello CM, Wondrak GT. (2009). The topical antimicrobial zinc pyrithione is a heat shock response inducer that causes DNA damage and PARP-dependent energy crisis in human sKin cells. Cell STREss Chaperones 15: 309-322.
18. Lamore SD, Wondrak GT. (2011). Zinc pyrithione impairs zinc homeostasis and upregulates sTREss response gene expression in reconstructed human epidermis. Biometals 24: 875-890.
19. Lopez-Lazaro M. (2007). Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 11: 1043-1053. (Pubitemid 47232620)
20. Metivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I et al. (1998). Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett 61: 157-163. (Pubitemid 28260991)
21. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D et al. (1991). Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766.
22. Newman RA, Yang P, Hittelman WN, Lu T, Ho DH, Ni D et al. (2006). Oleandrin-mediated oxidative sTREss in human melanoma cells. J Exp Ther Oncol 5: 167-181. (Pubitemid 43843828)
23. Newman RA, Yang P, Pawlus AD, Block Ki. (2008). Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8: 36-49. (Pubitemid 351398451)
24. Perne A, Muellner MK, Steinrueck M, Craig-Mueller N, Mayerhofer J, Schwarzinger I et al. (2009). Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 4: e8292.
25. Smits EL, Lee C, Hardwick N, Brooks S, Van Tendeloo VF, Orchard K et al. (2011). Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunol Immunother 60: 757-769.
26. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. (2005). Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106: 2841-2848. (Pubitemid 41510762)
27. Tufi R, PanaretaKis T, Bianchi K, Criollo A, Fazi B, Di Sano F et al. (2008). Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ 15: 274-282.
28. Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L et al. (2009). The inositol 1,4,5-trisphosphate receptor regulates autophagy through its inteRaction with Beclin 1. Cell Death Differ 16: 1006-1017.
29. Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, Senovilla L et al. (2007). Inhibition of Chk1 Kills tetraploid tumor cells through a p53-dependent pathway. PLoS One 2: e1337.
30. Wald DN, Vermaat HM, Zang S, Lavik A, Kang Z, Peleg G et al. (2008). Identification of 6-benzylthioinosine as a myeloid leukemia differentiation- inducing compound. Cancer Res 68: 4369-4376.
31. Wang Z, Zheng M, Li Z, Li R, Jia L, Xiong X et al. (2009). Cardiac glycosides inhibit p53 synthesis by a mechanism Relieved by Src or MAPK inhibition. Cancer Res 69: 6556-6564.
32. Weil M, Jacobson MD, Coles HS, Davies TJ, Gardner RL, Raff KD et al. (1996). Constitutive expression of the machinery for programmed cell death. J Cell Biol 133: 1053-1059. (Pubitemid 26172510)
33. Yin W, Li X, Feng S, Cheng W, Tang B, Shi YL et al. (2009). Plasma membrane depolarization and Na,K-ATPase impairment induced by mitochondrial toxins augment leukemia cell apoptosis via a novel mitochondrial amplification mechanism. Biochem Pharmacol 78: 191-202.
34. Zhang L, Nakaya K, Yoshida T, Kuroiwa Y. (1992). Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res 52: 4634-4641.